Eli Lilly and Co. LLY has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over the last month. Chart created using Benzinga ProLilly stock is well below its summer highs and is trading at $746.94 at the time of writing. The once red-hot obesity drugmaker is in the crosshairs of bearish technicals and political uncertainty.Could the selloff be an overreaction?Read Also: Eli Lilly, Verge Genomics Opt To Develop ALS Drug CandidateBearish Signals Galore For ...

— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug disc ...

Eli Lilly (LLY) announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) or Lp(a) levels in adults with high risk of cardiovascular events in a 12-week phase II study.In the study, muvalaplin led to a significant reduction in elevated Lp(a) levels compared to placebo, meeting the study’s primary endpoint of percent change in Lp(a) from baseline to week 12.  Using an intact Lp(a) assay, the reductions in Lp(a) levels were 47.6% for the 10 mg dose, 81.7% ...

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 studyThese data were published in the Journal of the American Medical Association (JAMA) and simultaneously presented today at the American Heart Association (AHA) Scientific Sessions 2024INDIANAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally ...

INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant Combination therapy to be evaluated as part of ongoing Phase 1/2 study in patients with HR+/HER2- metastatic breast cancer Incyclix will sponsor the trial and Lilly will provide Verzenio Incyclix plans to initiate combination cohorts with INX-315 in fourth quarter of 2024 RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle ...

The drugmaker Ely Lilly (LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well this year, rising roughly 36% (as of Nov. 14), ahead of the broader market.Given that Eli Lilly has been public for roughly seven decades, it's no surprise that it has conducted a few stock splits. When a company does a split, the amount of a shareholder's equity doesn't change but the number of shares does. Comp ...

In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitationsPatients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agenciesINDIANAPOLIS, Nov. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantl ...

Key TakeawaysEli Lilly has joined Johnson & Johnson in filing a lawsuit against the federal government over a decades-old drug discounting program.The companies have said the 340B program, which requires drugmakers to sell discounted medications to certain medical facilities, needs changes.The Health Resources and Services Administration, however, has rejected the companies' proposed changes to the program. Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting t ...

SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three yearsResults suggest one new case of diabetes could be prevented for every nine patients treated with tirzepatideParticipants treated with tirzepatide had an average weight reduction of 22.9% (15 mg dose)INDIANAPOLIS, Nov. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study ...

If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.Finding stocks that could quickly double or triple your money isn't hard. Just about every day, a Wall Street analyst issues a price target that suggests a relatively small and unestablished company could double or triple your money. Usually, though, the word "could" is working way too hard for such a risky investment to make sense for most investors.If you want to avoid the riskiest corners of the stock ...